Lineage Cell Therapeutics, Inc.
LCTX
$1.68
$0.074.35%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.59% | 96.38% | 4.02% | 37.36% | 203.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.59% | 96.38% | 4.02% | 37.36% | 203.29% |
| Cost of Revenue | -12.38% | 8.00% | 0.57% | -14.06% | -94.63% |
| Gross Profit | -2.02% | 74.73% | 2.70% | 65.81% | 233.97% |
| SG&A Expenses | -4.97% | 4.52% | -2.80% | 480.61% | 9.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.00% | 5.91% | -1.21% | 62.15% | -4.18% |
| Operating Income | 1.41% | 15.80% | 2.34% | -80.44% | 42.73% |
| Income Before Tax | -891.40% | -425.97% | 36.83% | 31.06% | 58.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -891.40% | -425.97% | 36.83% | 31.06% | 58.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 12.12% | -869.23% | -75.00% | 62.30% | -168.75% |
| Net Income | -881.58% | -428.89% | 36.73% | 31.46% | 57.33% |
| EBIT | 1.41% | 15.80% | 2.34% | -80.44% | 42.73% |
| EBITDA | 2.46% | 16.70% | 2.24% | -86.64% | 43.35% |
| EPS Basic | -708.07% | -337.38% | 48.88% | 50.18% | 60.44% |
| Normalized Basic EPS | -705.94% | -125.79% | 48.88% | -86.96% | 59.76% |
| EPS Diluted | -708.07% | -337.38% | 48.88% | 50.18% | 60.44% |
| Normalized Diluted EPS | -705.94% | -125.79% | 48.88% | -86.96% | 59.76% |
| Average Basic Shares Outstanding | 21.19% | 20.94% | 23.59% | 37.24% | 7.99% |
| Average Diluted Shares Outstanding | 21.19% | 20.94% | 23.59% | 37.24% | 7.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |